Lp(a)

What is Lp(a)?

Lipoprotein(a), Lp(a) for short, is a cholesterol particle with an extra 'sticky' protein around it. Your value is largely set at birth and stays fairly stable throughout your life. A high Lp(a) raises the risk of heart and vascular disease, independent of your other cholesterol values. Knowing where you stand once is valuable. It makes the other heart markers all the more important to keep sharp.

Clinical frame

Lp(a) is a genetically determined cholesterol particle: an LDL-like particle with apoB100 to which apolipoprotein(a) is attached. Its concentration is more than 90 % genetically fixed and remains stable lifelong. Lp(a) promotes atherosclerosis, vessel-wall inflammation, valve calcification and thrombosis, partly through the oxidised phospholipids it carries ^[1].

It is an independent, causal risk factor for cardiovascular disease and aortic valve stenosis, even with a low LDL or ApoB, and statins do not lower it. The risk rises continuously and becomes clinically relevant above 50 mg/dL (105 to 125 nmol/L), a threshold that one in five people exceeds ^{[1] [2]}.

One measurement in a lifetime suffices, preferably in nmol/L, because mass units depend on particle size and a fixed conversion is unreliable ^[3]. As long as specific Lp(a)-lowering drugs are still under investigation, an elevated value is above all a reason to tackle the other risk factors more strictly ^{[2] [3]}.

What moves this value?

Mainly hereditary. Lifestyle barely moves this value, so fluctuations are usually small.

Lp(a) itself is difficult to lower with lifestyle. The biggest gain lies in keeping your other heart markers such as ApoB and LDL extra calm. Discuss a raised value with your doctor.

What this connects

• ApoB

References

1. Kronenberg, F. et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 43, 3925–3946 (2022). doi.org/10.1093/eurheartj/ehac361
2. Mach, F. et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 46, 4359–4378 (2025). doi.org/10.1093/eurheartj/ehaf190
3. Koschinsky, M. L. et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol 18, e308–e319 (2024). doi.org/10.1016/j.jacl.2024.03.001